Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

Pere Puig; Nadina Erill; Marta Terricabras; Isaac Subirana; Judit González-García; Adrià Asensi-Puig; Michael J. Donovan; Lourdes Mengual; M. Teresa Agulló-Ortuño; Mireia Olivan; Antonio Alcaraz; José A. López-Martín; Inés De Torres; José Luis Rodríguez-Peralto; Alfredo Rodríguez-Antolín; Juan Morote; Víctor González-Rumayor

doi:10.1186/s13104-019-4100-z

Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

Pere Puig, Nadina Erill, Marta Terricabras, Isaac Subirana, Judit González-García, Adrià Asensi-Puig, Michael J. Donovan, Lourdes Mengual, M. Teresa Agulló-Ortuño, Mireia Olivan, Antonio Alcaraz, José A. López-Martín, Inés De Torres, José Luis Rodríguez-Peralto, Alfredo Rodríguez-Antolín, Juan Morote, Víctor González-Rumayor

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Objectives: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.

Original language	English
Article number	68
Journal	BMC Research Notes
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s13104-019-4100-z
State	Published - 30 Jan 2019

Keywords

Active β-catenin
HLA class1
Prostate cancer
Systems pathology
Wnt/β-catenin pathway

Access to Document

10.1186/s13104-019-4100-z

Cite this

Puig, P., Erill, N., Terricabras, M., Subirana, I., González-García, J., Asensi-Puig, A., Donovan, M. J., Mengual, L., Agulló-Ortuño, M. T., Olivan, M., Alcaraz, A., López-Martín, J. A., De Torres, I., Rodríguez-Peralto, J. L., Rodríguez-Antolín, A., Morote, J., & González-Rumayor, V. (2019). Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer. BMC Research Notes, 12(1), Article 68. https://doi.org/10.1186/s13104-019-4100-z

@article{385e3da03e5c4b35aeb2c67c13cb038d,

title = "Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer",

abstract = "Objectives: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.",

keywords = "Active β-catenin, HLA class1, Prostate cancer, Systems pathology, Wnt/β-catenin pathway",

author = "Pere Puig and Nadina Erill and Marta Terricabras and Isaac Subirana and Judit Gonz{\'a}lez-Garc{\'i}a and Adri{\`a} Asensi-Puig and Donovan, {Michael J.} and Lourdes Mengual and Agull{\'o}-Ortu{\~n}o, {M. Teresa} and Mireia Olivan and Antonio Alcaraz and L{\'o}pez-Mart{\'i}n, {Jos{\'e} A.} and {De Torres}, In{\'e}s and Rodr{\'i}guez-Peralto, {Jos{\'e} Luis} and Alfredo Rodr{\'i}guez-Antol{\'i}n and Juan Morote and V{\'i}ctor Gonz{\'a}lez-Rumayor",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = jan,

day = "30",

doi = "10.1186/s13104-019-4100-z",

language = "English",

volume = "12",

journal = "BMC Research Notes",

issn = "1756-0500",

publisher = "BioMed Central Ltd.",

number = "1",

}

Puig, P, Erill, N, Terricabras, M, Subirana, I, González-García, J, Asensi-Puig, A, Donovan, MJ, Mengual, L, Agulló-Ortuño, MT, Olivan, M, Alcaraz, A, López-Martín, JA, De Torres, I, Rodríguez-Peralto, JL, Rodríguez-Antolín, A, Morote, J & González-Rumayor, V 2019, 'Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer', BMC Research Notes, vol. 12, no. 1, 68. https://doi.org/10.1186/s13104-019-4100-z

TY - JOUR

T1 - Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

AU - Puig, Pere

AU - Erill, Nadina

AU - Terricabras, Marta

AU - Subirana, Isaac

AU - González-García, Judit

AU - Asensi-Puig, Adrià

AU - Donovan, Michael J.

AU - Mengual, Lourdes

AU - Agulló-Ortuño, M. Teresa

AU - Olivan, Mireia

AU - Alcaraz, Antonio

AU - López-Martín, José A.

AU - De Torres, Inés

AU - Rodríguez-Peralto, José Luis

AU - Rodríguez-Antolín, Alfredo

AU - Morote, Juan

AU - González-Rumayor, Víctor

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Objectives: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.

AB - Objectives: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.

KW - Active β-catenin

KW - HLA class1

KW - Prostate cancer

KW - Systems pathology

KW - Wnt/β-catenin pathway

UR - http://www.scopus.com/inward/record.url?scp=85060859416&partnerID=8YFLogxK

U2 - 10.1186/s13104-019-4100-z

DO - 10.1186/s13104-019-4100-z

M3 - Article

C2 - 30700322

AN - SCOPUS:85060859416

SN - 1756-0500

VL - 12

JO - BMC Research Notes

JF - BMC Research Notes

IS - 1

M1 - 68

ER -

Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this